Dr Reddy's wins DCGI approval for Zytorvi, an immunotherapy for advanced esophageal cancer
India's drug regulator has cleared a first-line immunotherapy combination for advanced esophageal squamous cell carcinoma, the form that makes up most of the country's cases.

Dr Reddy's Laboratories said on Wednesday, October 21, that the Drugs Controller General of India has approved Zytorvi (toripalimab) for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). The drug is cleared for use alongside the chemotherapy drugs cisplatin and paclitaxel.
The approval covers adults whose disease cannot be surgically removed, has returned, or has spread. In plain terms, these are patients at the hard end of a hard diagnosis, and the company says the nod is meant to widen their access to immunotherapy at the very start of treatment, not after other options have run out.
The scale of the problem explains the interest. According to the company, ESCC accounts for roughly 80 per cent of all esophageal cancer cases in India, so this is not a niche subtype.
Zytorvi works by targeting the PD-1 pathway. Its active ingredient is a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, which supports T-cell activity against cancer cells. Think of it as taking the brakes off the immune system's own search-and-destroy crew.
The approval rests on the Phase 3 JUPITER-06 trial. Per the company's release, adding toripalimab to paclitaxel and cisplatin cut the risk of disease progression or death by 42 per cent compared with chemotherapy alone. At the final overall-survival analysis, median survival was 17.7 months with the combination versus 12.9 months with chemotherapy alone, a gap of 4.8 months.
This is Zytorvi's second approved indication in India, following nasopharyngeal carcinoma. Dr Reddy's holds commercialisation rights for toripalimab in 21 countries under a 2023 agreement with Junshi Biosciences. The release did not mention pricing or launch timing, which will largely decide how many patients actually benefit.
Read the original report at Siasat.